Sánchez-Danés et al. found that a slow-cycling LGR5+ tumor population promotes basal cell carcinoma (BCC) relapse after treatment with the Hedgehog (Hh) pathway Smoothened inhibitor vismodegib in both mouse and human BCC [47]. Here, LGR5 is linked to neoplasm.